BlendRepair & Recovery

KLOW 80mg

Four-component investigative peptide blend designed to study concurrent soft-tissue repair, cellular remodeling, and inflammation modulation.

GHK-Cu (50 mg)BPC-157 (10 mg)TB-500 (10 mg)KPV (10 mg)

Mechanism

KLOW acts through concurrent biological targets by combining GHK-Cu-mediated collagen remodeling and angiogenesis, BPC-157-driven tissue cytoprotection, TB-500 actin-sequestering cellular migration, and KPV-mediated down-regulation of NF-κB inflammatory signaling.

Dosing

Standard documented research protocols begin with a daily subcutaneous total blend dose of 2,667 mcg (~10 units).

Reconstitution

Add 3.0 mL of bacteriostatic water to achieve an approximate total peptide concentration of 26.67 mg/mL.

Storage

Store the unmixed lyophilized vial at -20 °C protected from moisture and light; keep the reconstituted liquid refrigerated between 2 °C and 8 °C for up to 28 days without freezing.

Mix & measure KLOW 80mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure KLOW 80mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration26.7mg/mL

Draw volume0.100mL

On the syringe10.0units

Total doses in vial: 30.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	2,667 mcg total (1× daily)	~10 units (0.10 mL)
Weeks 3–6	4,000 mcg total (1× daily)	~15 units (0.15 mL)
Weeks 7–12	5,333 mcg total (1× daily)	~20 units (0.20 mL)

Reconstitution Steps

1
Disinfect the rubber stoppers of both the bacteriostatic water vial and the KLOW vial with fresh alcohol swabs and let air dry.
2
Draw 3.0 mL of bacteriostatic water using a sterile syringe.
3
Insert the needle into the KLOW vial at an angle, directing the diluent slowly down the glass wall to minimize agitation and foaming.
4
Gently rotate or roll the vial between your palms until the cake is fully dissolved; avoid vigorous shaking.
5
Affix a label noting the reconstitution date and calculated concentration, then immediately refrigerate at 2–8 °C.

Supplies Needed

Peptide Vial

Lyophilized multi-peptide blend vial containing 80 mg total active peptides.

Insulin Syringes (U-100)

0.3 mL, 0.5 mL, or 1.0 mL syringes used to accurately draw low-volume doses.

Bacteriostatic Water

Sterile diluent with 0.9% benzyl alcohol used to reconstitute the lyophilized powder.

Alcohol Swabs

Used for sanitizing vial tops and the injection site before needle insertion.

Why researchers study it

Tissue repair and cellular recovery models

Preclinical wound closure and injury remodeling

Targeted NF-κB inflammatory cascade modulation

Collagen synthesis and extracellular matrix support

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

KLOW is an investigational multi-peptide formulation combining four distinct research peptides in a single 80 mg lyophilized vial: 50 mg of GHK-Cu alongside 10 mg each of BPC-157, TB-500, and KPV. This specific 5:1:1:1 ratio allows laboratory investigators to study the concurrent administration of several popular regenerative compounds without requiring separate reconstitutions or micro-injections. Because all constituents are co-lyophilized, they maintain an interconnected dose relationship throughout the entire research cycle. Preclinical interest in KLOW centers around potential additive or complementary pathways involved in soft-tissue remodeling, wound healing, extracellular matrix maintenance, and localized cytokine suppression. GHK-Cu provides copper-dependent signaling for fibroblasts, BPC-157 and TB-500 promote cell migration and tissue repair, and KPV serves as a targeted anti-inflammatory fragment derived from alpha-MSH. This preparation is strictly categorized as a non-clinical research chemical and has not undergone human safety or efficacy verification. Because it includes BPC-157 and TB-500, researchers working with athletic physiology models must account for standard anti-doping prohibitions associated with these peptides.

References

1.Pickart et al., PubMed, 2018 — Copper tripeptide GHK-Cu and its roles in collagen synthesis, angiogenesis and skin remodelling
2.Sikiric et al., PubMed, 2020 — Body protection compound BPC-157 in preclinical soft-tissue, tendon and gut-repair models
3.Land et al., PubMed, 2021 — KPV tripeptide (Lys-Pro-Val) and anti-inflammatory NF-kB signaling modulation
4.Goldstein et al., PubMed, 2012 — Thymosin beta-4 active fragment (TB-500) regulation of actin and cell migration